Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

BRISBANE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the fourth quarter and 12 months ended December 31, 2008. InterMune reported a net loss for the fourth quarter of 2008 of $32.3 million, or $0.83 per share, compared with a net loss of $25.9 million, or $0.67 per share, in the fourth quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Fourth quarter and recent events have highlighted our very significant progress on pirfenidone and ITMN-191 (R7227). We recently reported results of our Phase 3 CAPACITY program for pirfenidone in idiopathic pulmonary fibrosis (IPF) and are now preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for the United States and European Union, respectively. We also reported very positive top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) and launched the innovative all-oral treatment study, INFORM-1, in patients chronically infected with the hepatitis C virus (HCV)."

Results for Fourth Quarter 2008

InterMune reported total revenue in the fourth quarter of 2008 of $7.4 million, compared with total revenue of $9.6 million in the fourth quarter of 2007. Total revenue in the fourth quarter of 2008 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $6.6 million, compared with $8.8 million in the fourth quarter of 2007, a decrease of 25%, reflecting lower off-label physician prescriptions of Actimmune for the treatment of IPF, which InterMune does not promote. Fourth quarter total revenue also included revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191, which totaled
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines and segments ... forecast of revenue. , Browse through the TOC ... get an idea of the in-depth analysis provided. ... in the Asia-Pacific bromine market, and is supported ... http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a volatile and ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Reportlinker.com announces that a new market research ... Enzymes: Sustainable Alternatives with Remarkable ... Enzymes are among the most ... host of different roles in a wide ...
... Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings, ... the firm as Managing Director in the Healthcare group of ... its life science business. He will report to Brian McCarthy, ... Since 2003, Matthias had worked at JMP Securities, where ...
... 2011 Children at Paterson Public School No. 5 ... of more than 200 volunteers from Roche, New Jersey ... organizers from non-profit KaBOOM!. The new playground provides the ... as well as children living in the neighborhood with ...
Cached Biology Technology:Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope 2Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope 3Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children 2Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children 3Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children 4
(Date:10/15/2014)... Fred Alt will be awarded the 44th Rosenstiel Award ... for his pioneering research exploring the mechanisms of genomic ... cancer cells. Alt is the second alumnus to win ... Nobel Prize in 2003. , Alt is the Charles ... at Harvard Medical School and an investigator at the ...
(Date:10/14/2014)... 14, 2014)—It,s been millions of years since T. ... led by Ohio University scientists is breathing life back ... through dinosaur snouts. The research has important implications for ... but to enhance the sense of smell and cool ... said Ohio University doctoral student Jason Bourke, lead author ...
(Date:10/14/2014)... oil supplements, rich in omega-3 fatty acids, do not reduce ... the heart can beat as fast as 150 beats a ... Montreal Heart Institute were published in the Journal of ... For the trial, 337 patients with atrial fibrillation not receiving ... fish oil a day or to placebo for up to ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... Symposium on Multimodality Cardiovascular Molecular Imaging ... cell therapy, leading-edge research in imaging technology and ... of cardiovascular receptors, vascular biology, myocardial metabolism and ... Partnership for Critical Markers of Disease will host ...
... million year old fossils reveal much earlier origins of modern ... The chances of an octopus corpse surviving long enough to ... only a single fossil species was known, and from fewer ... octopus is. Even if you have never encountered one in ...
... - NASA scientists analyzing the dust of meteorites have discovered ... on its most basic, molecular level. "We found more ... created in space and brought to Earth by meteorite impacts ... of NASA,s Goddard Space Flight Center in Greenbelt, Md. "By ...
Cached Biology News:SNM Symposium on Multimodality Cardiovascular Molecular Imaging 2Cretaceous octopus with ink and suckers -- the world's least likely fossils? 2NASA researchers find clues to a secret of life 2NASA researchers find clues to a secret of life 3
...
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
... Peroxidase Conjugate, 2 ml. ... enzyme molecules for use ... situ hybridization applications.High specificity ... Labeling & Detection, Protein ...
Biology Products: